Has anybody had this, or know anything about it? Who does it in NYC?

Jesse Lemisch
================================
Journal Article     Printable view
Transurethral ethanol ablation of the prostate (TEAP): an effective
minimally invasive treatment alternative to traditional surgery for
symptomatic benign prostatic hyperplasia (BPH) in high-risk
comorbidity patients
Transurethral ethanol ablation of the prostate (TEAP): an effective
minimally invasive treatment alternative to traditional surgery for
symptomatic benign prostatic hyperplasia (BPH) in high-risk
comorbidity patients
Journal    International Urology and Nephrology
Publisher    Springer Netherlands
ISSN    0301-1623 (Print) 1573-2584 (Online)
Category    Urology - Original Paper
DOI    10.1007/s11255-008-9394-z
Subject Collection    Medicine
SpringerLink Date    Wednesday, May 14, 2008

Add to marked items
Add to shopping cart
Add to saved items
Permissions & Reprints
Recommend this article
PDF (201.2 KB)HTML

Urology - Original Paper
Transurethral ethanol ablation of the prostate (TEAP): an effective
minimally invasive treatment alternative to traditional surgery for
symptomatic benign prostatic hyperplasia (BPH) in high-risk
comorbidity patients

Carlo Magno1 Contact Information, Giuseppe Mucciardi1, Alessandro
Galì1, Giuseppina Anastasi1, Antonino Inferrera1 and Giuseppe Morgia1
(1)      Department of Urology, University of Messina, Via Consolare
Valeria, Messina, 98100, Italy

Received: 30 November 2007  Accepted: 16 April 2008  Published online:
14 May 2008
Abstract
Objective  To evaluate the efficacy and safety of transurethral
ethanol ablation of the prostate (TEAP) for patients with symptomatic
benign prostatic hyperplasia (BPH) and high-risk comorbidities.
Materials and methods  Thirty-six patients (mean age 77.3 years) with
symptomatic BPH or persistent urinary retention were assessed at
baseline and at 3, 6, and 12 months after treatment. All patients were
affected by comorbidities (cardiovascular, respiratory, hematologic,
neoplastic, dysmetabolic diseases, or coagulation disorders). Baseline
evaluation was achieved by the International Prostate Symptom Score
(IPSS) and quality of life (QoL) score, prostate-specific antigen
(PSA), prostate transrectal ultrasound (TRUS), and the maximum peak
flow rate with evaluation of post-voiding residual urine volume (PVR).
Treatment was performed by injecting dehydrated ethanol at a rate
correlated to prostate volume into the prostate. The primary end-point
for response was ≥80% improvement of the maximum peak flow rate and
significant reduction of the PVR; secondary end-points included
symptom improvement (≥40% reduction in IPSS and QoL scores).
Statistical analysis was carried out with Pearson's Chi-square test
and the non-parametric Wilcoxon test with an assigned statistical
significance at P < 0.05.
Results  During the active follow-up period, we observed a
statistically significant decrease of the baseline at the end of the
study in the total IPSS score and in the QoL score. The mean peak flow
rate improved from 6.0 ± 2.40 ml/min to 15.2 ± 0.14 ml/min (P <
0.001), while the PVR decreased from a baseline value of 290.6 ± 14.14
ml to 4.2 ± 14.10 ml (P < 0.001).
Conclusion  We found that TEAP is a safe minimally invasive treatment,
which significantly improves voiding dysfunctions in patients with
symptomatic BPH.

Keywords  Transurethral ethanol ablation of the prostate (TEAP) -
Benign prostatic hyperplasia (BPH)

Contact Information     Carlo Magno
Email: carlo.magno@unime.it

References secured to subscribers.

more options
Find
Query Builder Close | Clear

   * Title (ti)
   * Summary (su)
   * Author (au)
   * ISSN (issn)
   * ISBN (isbn)
   * DOI (doi)
   *

   * And
   * Or
   * Not
   * (
   * )
   * * (wildcard)
   * "" (exact)

Within all content
Within this journal
Export this article
Export this article as RIS | Text

Frequently asked questions | General information on journals and books

(c) Springer. Part of Springer Science+Business Media
Privacy, Disclaimer, Terms and Conditions, (c) Copyright Information
Remote Address: 71.190.64.209 * Server: mpweb16
HTTP User Agent: Mozilla/5.0 (Windows; U; Windows NT 5.1; en-US; rv:
1.8.1.14) Gecko/20080404 Firefox/2.0.0.14